BR9610390A - O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i - Google Patents

O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i

Info

Publication number
BR9610390A
BR9610390A BR9610390A BR9610390A BR9610390A BR 9610390 A BR9610390 A BR 9610390A BR 9610390 A BR9610390 A BR 9610390A BR 9610390 A BR9610390 A BR 9610390A BR 9610390 A BR9610390 A BR 9610390A
Authority
BR
Brazil
Prior art keywords
pct
thienotriazolodiazepine
apoliprotein
increase levels
sec
Prior art date
Application number
BR9610390A
Other languages
English (en)
Portuguese (pt)
Inventor
Herman Kempen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9610390A publication Critical patent/BR9610390A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9610390A 1995-09-09 1996-08-30 O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i BR9610390A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09
PCT/EP1996/003814 WO1997009048A1 (en) 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Publications (1)

Publication Number Publication Date
BR9610390A true BR9610390A (pt) 1999-07-06

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610390A BR9610390A (pt) 1995-09-09 1996-08-30 O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i

Country Status (14)

Country Link
US (1) US5854238A (cg-RX-API-DMAC10.html)
EP (1) EP0853480B1 (cg-RX-API-DMAC10.html)
JP (1) JPH11512107A (cg-RX-API-DMAC10.html)
KR (1) KR19990044460A (cg-RX-API-DMAC10.html)
CN (1) CN1101680C (cg-RX-API-DMAC10.html)
AT (1) ATE230600T1 (cg-RX-API-DMAC10.html)
AU (1) AU725249B2 (cg-RX-API-DMAC10.html)
BR (1) BR9610390A (cg-RX-API-DMAC10.html)
CA (1) CA2230477A1 (cg-RX-API-DMAC10.html)
DE (1) DE69625696T2 (cg-RX-API-DMAC10.html)
DK (1) DK0853480T3 (cg-RX-API-DMAC10.html)
ES (1) ES2188783T3 (cg-RX-API-DMAC10.html)
TR (1) TR199800406T1 (cg-RX-API-DMAC10.html)
WO (1) WO1997009048A1 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20040235877A1 (en) 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
CN102292341B (zh) * 2008-10-30 2014-09-10 环行医学有限责任公司 对apo a有活性的噻吩并三唑并二氮杂*衍生物
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EA202092635A1 (ru) 2018-06-13 2021-03-23 Дибли Аг Получение конденсированных производных триазепина и их применение в качестве ингибиторов bet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
JPS50100096A (cg-RX-API-DMAC10.html) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
AU725249B2 (en) 2000-10-12
DE69625696D1 (de) 2003-02-13
CN1101680C (zh) 2003-02-19
EP0853480A1 (en) 1998-07-22
US5854238A (en) 1998-12-29
EP0853480B1 (en) 2003-01-08
ES2188783T3 (es) 2003-07-01
WO1997009048A1 (en) 1997-03-13
KR19990044460A (ko) 1999-06-25
DK0853480T3 (da) 2003-05-05
CN1195989A (zh) 1998-10-14
MX9801753A (es) 1998-08-30
ATE230600T1 (de) 2003-01-15
CA2230477A1 (en) 1997-03-13
AU6930396A (en) 1997-03-27
TR199800406T1 (en) 1998-05-21
JPH11512107A (ja) 1999-10-19
DE69625696T2 (de) 2003-10-16

Similar Documents

Publication Publication Date Title
DK0853480T3 (da) Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
TR200101969T2 (tr) Enflamasyon tedavisi için sübstitüe edilmiş benzopiran analogları.
DK0801564T3 (da) Anvendelse af nebivolol som et antiatherogent middel
NO981944L (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
EE9800080A (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
BR9916565A (pt) Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
BR9811099A (pt) Inibidores de urocinase
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
NO980296L (no) Forbedrede terapeutiske midler
AU4080097A (en) Piperazino derivatives as neurokinin antagonists
DE69629023D1 (de) Piperazino-derivative als neurokininantagonisten
ES2190471T3 (es) Procedimiento para producir derivados de guanidina, intermedios de dichos compuestos y su produccion.
ES2120667T3 (es) Sal de l-carnitina y composiciones cosmeticas y farmaceuticas que la contienen para tratamiento de dermatosis.
UA41350C2 (uk) Похідна морфоліну або її фармацевтично прийнятна сіль та фармацевтична композиція на її основі
DZ1965A1 (fr) Composition pharmaceutique nouvelle.
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
DE69412612D1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
SE9301831D0 (sv) Pharmaceutical compositions
AR005866A1 (es) Composicion farmaceutica antioxidante
ES2137665T3 (es) Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos.
ATE223427T1 (de) Modifizierte kojibioside analoge
BR9813098A (pt) Uso de glicosaminoglicans, preparação farmacêutica, e, combinaçào
AU675281B2 (en) Application of riluzole as a radiorestorer
ES2069146T3 (es) Medicamentos que contienen derivados sustituidos de 2-ciclohexeno-1-il-amina y su uso para combatir enfermedades.

Legal Events

Date Code Title Description
HHB Publication of an application: rectification
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRENTE PEDIDO, COM BASE NOS ARTIGOS 8 E 11 DA LPI E DADO COM CONCLUIDO O EXAME.